City of Hope | Strategic Alliance Partners

SER-155 showed early promise in reducing bloodstream infections in patients undergoing donor stem cell transplants for blood cancers.

See what leading breast oncologists have to say about practice-informing data to come out of the 2026 ESMO Congress.

Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.

Dr Chung discusses the development of atebimetinib in metastatic pancreatic cancer.

Lung cancer experts discuss emerging strategies after immunotherapy in advanced squamous NSCLC, including updated PRESERVE-003 data from WCLC 2026.

Faculty convened at an OncLive Scientific Interchange and Workshop to discuss individualized treatment and strategic sequencing in HER2-mutated NSCLC.

Drs Park and Kasi discuss the rise of neoadjuvant immunotherapy in CRC management, framing how this shift fits into the context of larger paradigm changes.

Novel approaches to the use of AI in oncology may require discussion and ultimately modification of existing proprietary and regulatory barriers.

Tycel Phillips, MD, discusses sonrotoclax’s FDA approval for mantle cell lymphoma and why the BCL2 inhibitor opens more possibilities.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.

Edward S. Kim, MD, MBA, discusses the purpose and value of the Bridging the Gaps in Lung Cancer meeting.

Two decades of biomarker-driven progress have reshaped lung cancer management, but late diagnosis, unequal treatment access, and underfunding remain

Alex Herrera, MD, discusses the FDA approval of nivolumab plus AVD for untreated classical Hodgkin lymphoma.

Marwan G. Fakih, MD, explains why obtaining a liquid biopsy at diagnosis is critical to avoid uninformative genomic results after starting chemotherapy.

Marwan G. Fakih, MD, discusses the clinical coordination of liquid and tissue biopsies and identifies when repeat ctDNA testing is over-utilized.

Public libraries will play a role in developing essential reading skills, improving financial literacy, and fostering critical thinking.

Marwan G. Fakih, MD, discusses how data from the POD1UM-303 trial support the use of retifanlimab in frontline squamous cell anal carcinoma.

The top 5 OncLive TV videos of the week cover insights in breast cancer, ovarian cancer, prostate cancer, acute myeloid leukemia, and mantle cell lymphoma.

Tycel Phillips, MD, discusses the FDA approval of sonrotoclax in mantle cell lymphoma and where the agent can be best applied in the treatment paradigm.

Marwan G. Fakih, MD, discusses the synergy between liquid and tissue biopsies and the need for a data-driven approach to repeat ctDNA testing in CRC.

Maurie Markman, MD, joins The Moonlight Shift to discuss precision medicine's real-world limits, oncology's cost crisis, CAR-T in solid tumors, and the decision support gap costing patients.

Marwan G. Fakih, MD, discusses the pitfalls of using liquid TMB for immunotherapy selection and the need for tissue-liquid biopsy concordance in CRC.

Alex Herrera, MD, discusses safety data and considerations for nivolumab plus AVD in classical hodgkin lymphoma.

The top 5 OncLive TV videos of the week cover insights in breast cancer, ovarian cancer, prostate cancer, acute myeloid leukemia, and mantle cell lymphoma.

Tycel Phillips, MD, discusses considerations for navigating treatment options in relapsed/refractory mantle cell lymphoma.

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.

Alex Herrera, MD, discusses the FDA approval of nivolumab plus AVD for classical Hodgkin lymphoma and its impact on clinical practice.

Drs Nunnery and Kang discuss the rapidly evolving treatment paradigm for first-line metastatic TNBC, including the emergence of novel ADCs.

Maurie Markman, MD, highlights the frequently complex arena of goals of care discussions in oncology.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, head and neck cancer, breast cancer, prostate cancer, and leukemia.